EGFR and neoplasm: Using the TaqMan assay, a qualitative method, to detect EGFR mutations in plasma, it showed that median OS was significantly shorter in patients with both tumor and plasma L858R mutation (13.7 months) than in tumor-only L858R-positive patients (27.7 months) 19].